SPY391.86-16.46 -4.03%
DIA315.55-11.55 -3.53%
IXIC11,418.15-566.37 -4.73%

Kazia Therapeutics to Present Final Data From Its Paxalisib Phase 2 Study In Glioblastoma At American Society For Clinical Oncology Jun 5, 2022 at 9 a.m.-12 p.m. EDT

Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will

Benzinga · 04/29/2022 11:01

Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO).

Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)

The ASCO Annual Meeting will take place virtually and in person from 3-7 June 2022 and will be held in Chicago, IL.

Abstracts from the meeting are expected to be released from 5pm, ET, on 26 May 2022, and the poster will be made available by ASCO and via the Kazia website shortly after presentation.  

POSTER PRESENTATION

Title: Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.
Date and Time: Sunday, 5 June 2022 – 8am – 11am, CDT
Session: Central Nervous System Tumors
Abstract ID: 2047